The genomic profile of HER2 ‐amplified breast cancers: the influence of ER status-Reference-Cited by-同舟云学术

The genomic profile of HER2 ‐amplified breast cancers: the influence of ER status

Published:2008-09-22 Issue:4 Volume:216 Page:399-407
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Marchiò C¹²,Natrajan R¹,Shiu KK¹,Lambros MBK¹,Rodriguez‐Pinilla SM³,Tan DSP¹,Lord CJ¹,Hungermann D⁴,Fenwick K¹,Tamber N¹,Mackay A¹,Palacios J⁵,Sapino A²,Buerger H⁴,Ashworth A¹,Reis‐Filho JS¹

Affiliation:

1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK

2. Department of Biomedical Sciences and Human Oncology, University of Turin, Italy

3. Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

4. Institute of Pathology, Paderborn, Germany

5. Hospital Universitario Virgen del Rocío, Seville, Spain

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/path.2423

Reference53 articles.

1. Phase II study of weekly intravenous Trastuzumab (Herceptin) in patients with HER2/neu‐overexpressing metastatic breast cancer;Baselga J;Semin Oncol,1999

2. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

3. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

4. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

5. Molecular portraits of human breast tumours

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab;Cancer Chemotherapy and Pharmacology;2022-10-20

2. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival;ESMO Open;2021-08

3. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond;Seminars in Cancer Biology;2021-07

4. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer;BMC Cancer;2019-11-01

5. The Estrogen-Regulated Transcriptome: Rapid, Robust, Extensive, and Transient;Estrogen Receptor and Breast Cancer;2018-10-17